Neuroprotection for Stroke: Current Status and Future Perspectives
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Neuroprotection aims to prevent salvageable neurons from dying. Despite showing efficacy in experimental stroke studies, the concept of neuroprotection has failed in clinical trials. Reasons for the translational difficulties include a lack of methodological agreement between preclinical and clinical studies and the heterogeneity of stroke in humans compared to homogeneous strokes in animal models. Even when the international recommendations for preclinical stroke research, the Stroke Academic Industry Roundtable (STAIR) criteria, were followed, we have still seen limited success in the clinic, examples being NXY-059 and haematopoietic growth factors which fulfilled nearly all the STAIR criteria. However, there are a number of neuroprotective treatments under investigation in clinical trials such as hypothermia and ebselen. Moreover, promising neuroprotective treatments based on a deeper understanding of the complex pathophysiology of ischemic stroke such as inhibitors of NADPH oxidases and PSD-95 are currently evaluated in preclinical studies. Further concepts to improve translation include the investigation of neuroprotectants in multicenter preclinical Phase III-type studies, improved animal models, and close alignment between clinical trial and preclinical methodologies. Future successful translation will require both new concepts for preclinical testing and innovative approaches based on mechanistic insights into the ischemic cascade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Thresholds in cerebral ischemia - the ischemic penumbra.
Astrup, J., Siesjö, B. K., & Symon, L. (1981) · Stroke · doi:10.1161/01.str.12.6.723 · Cited by 2,820 · cited 1×
“Surrounding the core is the penumbra [3], a region that has reduced blood flow but neurons remain quiescent due to a collateral blood supply.”
BackgroundRegulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Role of oxidative stress in cardiovascular diseases
Dhalla, N. S., Temsah, R. M., & Netticadan, T. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018060-00002 · Cited by 1,467 · cited 1×
“Free radical formation including ROS (reactive oxygen species) contributes to secondary infarct growth [99–101].”
BackgroundUpdate of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352 · cited 2×
“This variability can be attributed to the low methodological quality of many neuroprotective studies [9], based on the STAIR criteria [12,13].”
BackgroundMethodNXY-059 for Acute Ischemic Stroke
Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.564872 · Cited by 605
Publication bias in reports of animal stroke studies leads to major overstatement of efficacy
Sena, E. S., van der Worp, H. B., Bath, P. M. W., Howells, D. W., & Macleod, M. R. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000344 · Cited by 600 · cited 1×
“the overestimation of a treatment’s efficacy, was followed by some stroke journals by increasing the number of publications containing animal studies with neutral results [89–91].”
Kleinschnitz, C., Grund, H., Wingler, K., Armitage, M. E., Jones, E., Mittal, M., Barit, D., Schwarz, T., Geis, C., Kraft, P., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000479 · Cited by 447 · cited 2×
“NOX4-derived oxidative stress plays a pivotal role in the pathophysiology of cerebral ischemia [106,107].”
BackgroundSelf-citationHermann, D. M., & Chopp, M. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70039-x · Cited by 333 · cited 1×
“Other strategies to improve outcome after stroke include treatments that promote neurological recovery by remodeling of brain tissue (for a review see [92]).”
BackgroundMacleod, M. R., van der Worp, H. B., Sena, E. S., Howells, D. W., Dirnagl, U., & Donnan, G. A. (2008) · Stroke · doi:10.1161/strokeaha.108.515957 · Cited by 319 · cited 3×
“Overall, there is a need for a more rigorous design of animal stroke studies with higher quality standard levels to avoid bias [7,57].”
BackgroundNeuroprotection for Ischaemic Stroke: Translation from the Bench to the Bedside
Sutherland, B. A., Minnerup, J., Balami, J. S., Arba, F., Buchan, A. M., & Kleinschnitz, C. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2012.00770.x · Cited by 259 · cited 5×
“window, small sample sizes, and failure to achieve sufficient plasma levels of treatments [6,84,85].”
BackgroundInfluentialSelf-citationImplications of vascular endothelial growth factor for postischemic neurovascular remodeling
Hermann, D. M., & Zechariah, A. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.100 · Cited by 162
Cited by
Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke
Liu, Z., & Chopp, M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.008 · Cited by 590
Molecular pathophysiology of cerebral edema
Stokum, J. A., Gerzanich, V., & Simard, J. M. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15617172 · Cited by 587
Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K., & Schmidt, H. H. H. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5814 · Cited by 521
Role of Inflammation and Its Mediators in Acute Ischemic Stroke
Jin, R., Liu, L., Zhang, S., Nanda, A., & Li, G. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9508-6 · Cited by 418
Zhu, T., Wang, L., Wang, L.-P., & Wan, Q. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112719 · Cited by 287
Metadata
- Authors
- Minnerup, J., Sutherland, B. A., Buchan, A. M., & Kleinschnitz, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-09-18
- Volume
- 13
- Issue
- 9
- Pages
- 11753-11772
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W1980249915
- Cited by
- 205
- References
- 14
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.